Maria Aquino

Mrs. Maria Aquino

Faculty of Pharmacy, University of Coimbra, Coimbra, Portugal
+1
orcid
Curious Junior Scientist

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 February 2024 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
FBFrancisca Bastos
Francisca Bastos
ATAndreia Tabanez
Andreia Tabanez
Maria AquinoMaria Aquino
Maria Aquino
ANAntónio Nunes
António Nunes
SSSérgio Simões
Sérgio Simões

11 February 2023 in Antibiotics
Verified
Journal Article
Open access
PDF file
Maria AquinoMaria Aquino
Maria Aquino
MTMaria Tinoco
Maria Tinoco
Joana BickerJoana Bicker
Joana Bicker
AFAmílcar Falcão
Amílcar Falcão
MRMarília Rocha
Marília Rocha
Ana FortunaAna Fortuna
Ana Fortuna
Amikacin is the antibiotic of choice for the treatment of Gram-negative infections, namely, those in neutropenic oncology patients. No populational pharmacokinetic studies are currently available reporting amikacin pharmacokinetics in neutropenic oncology patients despite their specific pathophysiological features and treatments. A large-scale retrospective study was herein conducted to specifically investigate the effects that tumor diseases have on the pharmacokinetic parameters of amikacin and identify whether chemotherapy, the lag time between administration of chemotherapy and amikacin, age and renal function contribute to amikacin pharmacokinetics in neutropenic cancer patients. A total of 1180 pharmacokinetic analysis from 629 neutropenic patients were enrolled. The daily dose administered to oncology patients was higher than that administered to non-oncology patients (p < 0.0001). No statistical differences were found in amikacin concentrations, probably because drug clearance was increased in cancer patients (p < 0.0001). Chemotherapy influenced amikacin pharmacokinetics and drug clearance decreased as the lag time enhanced. The elderly group revealed no statistical differences between the doses administered to both the oncology groups, suggesting that the impact of ageing is stronger than chemotherapy. Our research suggests that cancer patients require higher initial doses of amikacin, as well as when chemotherapy is received less than 30 days before amikacin treatment has started.